X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

LRMR

Closed

Larimar Therapeutics Inc

2.88
-0.01 (-0.35%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.89
Day's Range: 2.81 - 2.98
Send
When Written:
 
4.47
Larimar Therapeutics Inc. is a clinical-stage biotechnology company that specializes in developing treatments for rare diseases. The company was founded in 2018 and is headquartered in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics' main focus is on developing treatments for Friedreich's ataxia (FA), a rare, progressive neurodegenerative disease that affects approximately 5,000 people in the United States. The company's lead drug candidate, CTI-1601, is a recombinant fusion protein that is designed to increase the expression of frataxin, a protein that is deficient in FA patients.

In addition to its work on FA, Larimar Therapeutics is also exploring the potential of CTI-1601 for the treatment of other rare diseases that are caused by frataxin deficiency. The company is also developing other drug candidates that target rare diseases with high unmet medical needs.

Larimar Therapeutics is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "LRMR".

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X